In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes.
about
In vitro and in vivo assessment of the anti-malarial activity of Caesalpinia pluviosaIn Vitro Resistance Selections for Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors Give Mutants with Multiple Point Mutations in the Drug-binding Site and Altered GrowthPfCRT and its role in antimalarial drug resistanceAtypical mitogen-activated protein kinase phosphatase implicated in regulating transition from pre-S-Phase asexual intraerythrocytic development of Plasmodium falciparumIdentification of a mutant PfCRT-mediated chloroquine tolerance phenotype in Plasmodium falciparumSimplified Reversed Chloroquines To Overcome Malaria Resistance to Quinoline-Based DrugsA non-radioactive DAPI-based high-throughput in vitro assay to assess Plasmodium falciparum responsiveness to antimalarials--increased sensitivity of P. falciparum to chloroquine in SenegalIdentification of inhibitors for putative malaria drug targets among novel antimalarial compounds.In vitro antiplasmodial activity of cepharanthine.Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria.In vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, quinine, mefloquine and halofantrine in Abidjan (Côte d'Ivoire)Diversity-oriented synthesis-facilitated medicinal chemistry: toward the development of novel antimalarial agentsBioactivity guided fractionation of leaves extract of Nyctanthes arbor tristis (Harshringar) against P falciparum.In vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations that include the resistance reversal agent amlodipineIdentification and deconvolution of cross-resistance signals from antimalarial compounds using multidrug-resistant Plasmodium falciparum strainsA novel inhibitor of Plasmodium falciparum spermidine synthase: a twist in the tailIdentifying apicoplast-targeting antimalarials using high-throughput compatible approachesUtilizing diversity-oriented synthesis in antimicrobial drug discovery.Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporter.Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies.In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assaysMonitoring antimalarial drug efficacy: current challenges.Reduced ex vivo susceptibility of Plasmodium falciparum after oral artemether-lumefantrine treatment in Mali.Hits, leads and drugs against malaria through diversity-oriented synthesis.Recent advances in novel heterocyclic scaffolds for the treatment of drug-resistant malaria.Salinomycin and other ionophores as a new class of antimalarial drugs with transmission-blocking activity.Antiprotozoal activities of organic extracts from French marine seaweeds.Assessment of malaria in vitro drug combination screening and mixed-strain infections using the malaria Sybr green I-based fluorescence assay.New hope in the fight against malaria?Long-Lasting and Fast-Acting in Vivo Efficacious Antiplasmodial Azepanylcarbazole Amino Alcohol.Checks and balances? DNA replication and the cell cycle in Plasmodium.
P2860
Q21034096-EE90D823-D784-4AAD-B784-6BE4318827ABQ27683596-F367FCB9-5B59-4B65-BAC3-95A5571592F8Q27861957-FC5EDB6E-65CB-48DC-B5F2-7A4855EA7D67Q27974726-C5DC088F-9790-4784-884A-944BCBA46167Q28473923-EE0FECD0-325E-4A74-A05B-E254C9C80FD7Q33601788-88C0AB60-C256-4173-A96E-320F5C05C677Q33617554-F48EC10C-FBCC-4E31-900D-0C70BD09647CQ33682916-E0C1B22C-FCB9-46EA-8A76-01B437857E3AQ34123636-16EBAB3F-EF48-40F1-B2BA-0C4167652D9CQ34157359-EA8B779A-BB46-4CBA-BC4B-DB1E2914AC44Q34206442-16A2E2F7-763C-4CB4-8F83-D1C666997A3DQ34394236-5A6FA3B1-E2FA-40FA-A06A-24491A0D15BAQ34540216-7CCBB303-6480-4087-9FCF-E121BA39E100Q35065754-362B61B8-45B7-4006-99B5-CC634F068A30Q35106020-F7166489-4E46-4D71-A427-85A45C5C2215Q35125370-66E04F57-083C-4E9D-A249-650751C9E662Q35225061-43BA4E97-3CAE-454D-A88D-6801705D81C8Q35510383-BB4C14A5-C1F4-4465-B38D-72E65E4E4CF3Q35879787-BCBA0E93-2283-4794-97BE-9512B37644B7Q36919648-3E659BCD-E92D-42B1-A939-589C7878AB9BQ37184295-BDDFB58A-8E46-44A8-9429-A4FFB64A09F2Q37225083-DBC6C4B5-62EE-4ABF-AB34-069EC7619FB6Q37621092-DA5F9AF8-128B-4A1C-ACE4-E7F4DC4B51D6Q38066992-DF9073F6-E56A-4812-A2AE-A6951BCF1257Q38379720-4358211C-AAA8-4C8C-8448-0F88ABFC7952Q38866063-AE4BA133-DD81-4DC4-98D3-884AFC16AA0EQ39508595-F48B5213-FE9F-4099-84CA-BA87480BBD0FQ41900287-7F0275D8-1361-4B85-9D3D-EEEF17B6A52BQ47590608-383F65E3-9174-4808-A414-B0A98639DFE6Q48019708-3C7103AF-237A-4D53-9595-6C9E8006DE27Q52627214-773DD770-8A57-4FBC-9335-2FABC4B26BD3
P2860
In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes.
@en
In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes.
@nl
type
label
In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes.
@en
In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes.
@nl
prefLabel
In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes.
@en
In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes.
@nl
P2860
P1476
In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes.
@en
P2093
Eric H Ekland
P2860
P304
P356
10.1016/J.IJPARA.2008.03.004
P577
2008-04-01T00:00:00Z